Sex and age differences in atrophic rates: an ADNI study with n =1368 MRI scans

Abstract We set out to determine factors that influence the rate of brain atrophy in 1-year longitudinal magnetic resonance imaging (MRI) data. With tensor-based morphometry (TBM), we mapped the 3-dimensional profile of progressive atrophy in 144 subjects with probable Alzheimer's disease (AD)...

Full description

Saved in:
Bibliographic Details
Published in:Neurobiology of aging 2010-08, Vol.31 (8), p.1463-1480
Main Authors: Hua, Xue, Hibar, Derrek P, Lee, Suh, Toga, Arthur W, Jack, Clifford R, Weiner, Michael W, Thompson, Paul M
Format: Article
Language:English
Subjects:
Age
Age Factors
Aged
Aged, 80 and over
Alzheimer Disease - pathology
Alzheimer's disease
Atrophy
Atrophy rate
Biomarker
Cognition Disorders - pathology
Disease Progression
Drug trial enrichment
Female
Follow-Up Studies
Humans
Internal Medicine
Longitudinal
Longitudinal Studies
Magnetic Resonance Imaging - methods
Male
Middle Aged
Mild cognitive impairment
MRI
Neuroimaging
Neurology
Prospective Studies
Sex Characteristics
Sex effect
Tensor-based morphometry
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract We set out to determine factors that influence the rate of brain atrophy in 1-year longitudinal magnetic resonance imaging (MRI) data. With tensor-based morphometry (TBM), we mapped the 3-dimensional profile of progressive atrophy in 144 subjects with probable Alzheimer's disease (AD) (age: 76.5 ± 7.4 years), 338 with amnestic mild cognitive impairment (MCI; 76.0 ± 7.2), and 202 healthy controls (77.0 ± 5.1), scanned twice, 1 year apart. Statistical maps revealed significant age and sex differences in atrophic rates. Brain atrophic rates were about 1%–1.5% faster in women than men. Atrophy was faster in younger than older subjects, most prominently in mild cognitive impairment, with a 1% increase in the rates of atrophy and 2% in ventricular expansion, for every 10-year decrease in age. TBM-derived atrophic rates correlated with reduced beta-amyloid and elevated tau levels ( n = 363) at baseline, baseline and progressive deterioration in clinical measures, and increasing numbers of risk alleles for the ApoE4 gene. TBM is a sensitive, high-throughput biomarker for tracking disease progression in large imaging studies; sub-analyses focusing on women or younger subjects gave improved sample size requirements for clinical trials.
ISSN:0197-4580
1558-1497
DOI:10.1016/j.neurobiolaging.2010.04.033